• Figure 1.

    The landscape of clinical trials in IgA nephropathy over the past 3 decades

  • 1.

    Rajasekaran A, et al. IgA nephropathy: An interesting autoimmune kidney disease. Am J Med Sci 2021; 361:176194. doi: 10.1016/j.amjms.2020.10.003

  • 2.

    Thompson A, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 2019; 14:469481. doi: 10.2215/CJN.08600718

  • 3.

    Rovin BH, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:753779. doi: 10.1016/j.kint.2021.05.015

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Lv J, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 2022; 327:18881898. doi: 10.1001/jama.2022.5368

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Barratt J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int [published online ahead of print October 19, 2022]. https://www.sciencedirect.com/science/article/pii/S0085253822008365

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Wong M, et al. MO209: Baseline characteristics of adults enrolled in the ongoing phase 3 randomized, double-blind, active-control trial of sparsentan for the treatment of immunoglobulin A nephropathy (PROTECT). Nephrol Dial Transplant 2022; 37 (Suppl. 3):i142i144. https://academic.oup.com/ndt/article/37/Supplement_3/gfac067.008/6578479?login=false

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Wheeler DC, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 2021; 100:215224. doi: 10.1016/j.kint.2021.03.033

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    EMPA-KIDNEY Collaborative Group; Herrington WG, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med, published online ahead of print November 4, 2022. doi: 10.1056/NEJMoa2204233

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Cheung CK, et al. An update on the current state of management and clinical trials for IgA nephropathy. J Clin Med 2021; 10:2493. doi: 10.3390/jcm10112493

The Rapidly Changing Landscape of IgA Nephropathy Treatment

Dana V. Rizk Dana V. Rizk, MD, is professor, Division of Nephrology, Internal Medicine, University of Alabama at Birmingham.

Search for other papers by Dana V. Rizk in
Current site
Google Scholar
PubMed
Close
Restricted access
Save